Therapeutic Vaccination Strategies for Breast Cancer

Abstract

Even though the impact of the immune system on the clinical course of cancer has been known for decades, its role in the treatment of various tumor entities has often been given little consideration. In recent years, the treatment landscape for breast cancer has undergone significant changes. Routine treatment has been revolutionized, in particular, by the use of T cell-based immunotherapies in the form of immune checkpoint inhibitors (ICIs). While this underscores the importance of the immune system in the treatment of breast cancer, other T cell-based immunotherapies, such as therapeutic vaccines, do still not play a significant role in clinical practice. In recent years, numerous studies on various vaccine candidates have been conducted, some of which have demonstrated a successful induction of an immune response. The selection of antigens and routes of administration/adjuvants capable of inducing long-lasting and clinically effective T cell responses remains a key challenge. The combination of ICIs with therapeutic vaccines could also hold promise for the future, by enhancing the specificity of the T cell response and thus augmenting the anti-tumor effect.

Keywords

Breast Cancer - Therapy - Vaccination

Publication History

Article published online:
13 September 2024

• References

• 1 Cortes J, Rugo HS, Cescon DW. et al. Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. N Engl J Med 2022; 387 (03) 217-226
• 2 Schmid P, Cortes J, Pusztai L. et al. Pembrolizumab for Early Triple-Negative Breast Cancer. N Engl J Med 2020; 382 (09) 810-821
• 3 Baxi S, Yang A, Gennarelli RL. et al. Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. Bmj 2018; 360: k793
• 4 Morisaki T, Kubo M, Umebayashi M. et al. Neoantigens elicit T cell responses in breast cancer. Sci Rep 2021; 11 (01) 13590
• 5 Chabanon RM, Pedrero M, Lefebvre C. et al. Mutational Landscape and Sensitivity to Immune Checkpoint Blockers. Clin Cancer Res 2016; 22 (17) 4309-4321
• 6 Schuster H, Peper JK, Bösmüller HC. et al. The immunopeptidomic landscape of ovarian carcinomas. Proc Natl Acad Sci U S A 2017; 114 (46) E9942-e9951
• 7 Walz S, Stickel JS, Kowalewski DJ. et al. The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy. Blood 2015; 126 (10) 1203-1213
• 8 Zhu SY, Yu KD. Breast Cancer Vaccines: Disappointing or Promising?. Front Immunol 2022; 13: 828386
• 9 Corti C, Giachetti P, Eggermont AMM. et al. Therapeutic vaccines for breast cancer: Has the time finally come?. Eur J Cancer 2022; 160: 150-174
• 10 Vishweshwaraiah YL, Dokholyan NV. mRNA vaccines for cancer immunotherapy. Front Immunol 2022; 13: 1029069
• 11 Paston SJ, Brentville VA, Symonds P. et al. Cancer Vaccines, Adjuvants, and Delivery Systems. Front Immunol 2021; 12: 627932
• 12 McCann N, O’Connor D, Lambe T. et al. Viral vector vaccines. Curr Opin Immunol 2022; 77: 102210
• 13 Nelde A, Rammensee HG, Walz JS. The Peptide Vaccine of the Future. Mol Cell Proteomics 2021; 20: 100022
• 14 Perez CR, De Palma M. Engineering dendritic cell vaccines to improve cancer immunotherapy. Nat Commun 2019; 10 (01) 5408
• 15 Curigliano G, Spitaleri G, Pietri E. et al. Breast cancer vaccines: a clinical reality or fairy tale?. Ann Oncol 2006; 17 (05) 750-762
• 16 Peoples GE, Gurney JM, Hueman MT. et al. Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. J Clin Oncol 2005; 23 (30) 7536-7545
• 17 Holmes JP, Benavides LC, Gates JD. et al. Results of the first phase I clinical trial of the novel II-key hybrid preventive HER-2/neu peptide (AE37) vaccine. J Clin Oncol 2008; 26 (20) 3426-3433
• 18 Mittendorf EA, Storrer CE, Foley RJ. et al. Evaluation of the HER2/neu-derived peptide GP2 for use in a peptide-based breast cancer vaccine trial. Cancer 2006; 106 (11) 2309-2317